GSK quad flu vaccine to shake up Germany and UK
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline is poised to take a bigger slice of the influenza prevention market, which, Datamonitor says is worth $3.5 billion in the US, Japan and EU big five. Germany and the UK have approved the quadrivalent flu vaccine under the decentralized procedure and GSK expects to be able to compete in the 2013/13 flu season.
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.